ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

In Vitro/In Vivo Preparation and Evaluation of cRGDyK Peptide-Modified Polydopamine-Bridged Paclitaxel-Loaded Nanoparticles

Yun, Dan; Liu, Dengyuan; Liu, Jinlin; Feng, Yanyi; Chen, Hongyu; Chen, Simiao; Xie, Qingchun*广东药学院
Pharmaceutics2023-11DOI: 10.3390/pharmaceutics15112644
4阅读
引用收藏
分享

摘要

Cancer remains a disease with one of the highest mortality rates worldwide. The poor water solubility and tissue selectivity of commonly used chemotherapeutic agents contribute to their poor efficacy and serious adverse effects. This study proposes an alternative to the traditional physicochemically combined modifications used to develop targeted drug delivery systems, involving a simpler surface modification strategy. cRGDyK peptide (RGD)-modified PLGA nanoparticles (NPs) loaded with paclitaxel were constructed by coating the NP surfaces with polydopamine (PD). The average particle size of the produced NPs was 137.6 +/- 2.9 nm, with an encapsulation rate of over 80%. In vitro release tests showed that the NPs had pH-responsive drug release properties. Cellular uptake experiments showed that the uptake of modified NPs by tumor cells was significantly better than that of unmodified NPs. A tumor cytotoxicity assay demonstrated that the modified NPs had a lower IC50 and greater cytotoxicity than those of unmodified NPs and commercially available paclitaxel formulations. An in vitro cytotoxicity study indicated good biosafety. A tumor model in female BALB/c rats was established using murine-derived breast cancer 4T1 cells. RGD-modified NPs had the highest tumor-weight suppression rate, which was higher than that of the commercially available formulation. PTX-PD-RGD-NPs can overcome the limitations of antitumor drugs, reduce drug toxicity, and increase efficacy, showing promising potential in cancer therapy.

学科与关键词

关键词
nanoparticlesRGDPLGAsurface modificationantitumor effect
相关
加载中…
  • Recent Research Progress of RGD Peptide-Modified Nanodrug Delivery Systems in Tumor Therapy
    Yin, Liyan; Li, Xingchen; Wang, Rongrong; Zeng, Yiying; Zeng, Zhaowu*; Xie, Tian*International Journal of Peptide Research and Therapeutics, 2023, 29(4): 53.被引 1
  • Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation in Vivo
    Ma, Peilin; Huang, JiaYing; Liu, Jinling; Zhu, Yi; Cheng, Jiahong; Cheng, Junming; Lei, Lunwen; Guan, Ziyun; Ban, Junfeng*; Lu, Zhufen*American Journal of Cancer Research, 2023, 14(5): 759-769.
  • Development of ligand modified erythrocyte coated polydopamine nanomedicine to codeliver chemotherapeutic agent and oxygen for chemo-photothermal synergistic cancer therapy
    Zhang, Liyao; Huang, Peijie; Huang, Shubin; Wang, Tao; Chen, Shufeng; Chen, Zhihao; Zhou, Yi*; Qin, Linghao*International Journal of Pharmaceutics, 2022, 626: 122156.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Pharmaceutics
发表日期
2023-11
卷期
第 15 卷, 第 11 期
页码
2644
DOI
10.3390/pharmaceutics15112644
成果收录
SCIE
资助标注
Innovation Project of Guangdong Graduate Education funded by Guangdong Pharmaceutical University

作者

  • Y

    Yun, Dan (第一作者)

    guangdong pharmaceut univ · new

  • L

    Liu, Dengyuan

    guangdong pharmaceut univ · new

查看全部 7 位作者收起作者
  • L

    Liu, Jinlin

    guangdong pharmaceut univ · new

  • F

    Feng, Yanyi

    guangdong pharmaceut univ · new

  • C

    Chen, Hongyu

    guangdong pharmaceut univ · new

  • C

    Chen, Simiao

    guangdong pharmaceut univ · new

  • X

    Xie, Qingchun (通讯)

    guangdong pharmaceut univ · new

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417